Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 04-Oct-24 7:15 PM View:  | Lyons Gary A Director | Travere Therapeutics, Inc. (TVTX) | 04-Oct-24 | Option Exercise | 40,000 | $10.48 | $419,200.00 | 78% 51.0K to 91.0K | |
| 04-Oct-24 7:15 PM View: | Lyons Gary A Director | Travere Therapeutics, Inc. (TVTX) | 04-Oct-24 | Planned Option Sale | 40,000 | $14.73 | $589,101.00 | (44%) 91.0K to 51.0K | |
| 30-Sep-24 8:38 PM View: | Meckler Jeffrey A Director | Travere Therapeutics, Inc. (TVTX) | 30-Sep-24 | Option Exercise | 40,000 | $10.48 | $419,200.00 | 49% 81.0K to 121.0K | |
| 30-Sep-24 8:38 PM View: | Meckler Jeffrey A Director | Travere Therapeutics, Inc. (TVTX) | 30-Sep-24 | Planned Option Sale | 40,000 | $14.06 | $562,324.00 | (33%) 121.0K to 81.0K | |
| 10-Sep-24 4:05 PM View: | Inrig Jula Chief Medical Officer | Travere Therapeutics, Inc. (TVTX) | 10-Sep-24 | Sale (Planned) | 684 | $12.98 | $8,878.32 | (1%) 62.63K to 61.95K | |
| 09-Sep-24 9:20 PM View: | Heerma Peter Chief Commercial Officer | Travere Therapeutics, Inc. (TVTX) | 09-Sep-24 | Sale | 2,191 | $11.52 | $25,240.30 | (2%) 110.15K to 107.96K | |
| 09-Sep-24 9:20 PM View: | Cline Christopher R. Chief Financial Officer | Travere Therapeutics, Inc. (TVTX) | 09-Sep-24 | Sale | 2,490 | $11.52 | $28,684.80 | (3%) 77.08K to 74.59K | |
| 09-Sep-24 9:20 PM View: | Dube Eric M Chief Executive Officer Director | Travere Therapeutics, Inc. (TVTX) | 09-Sep-24 | Sale (Planned) | 21,125 | $11.52 | $243,360.00 | (6%) 383.1K to 361.98K | |
| 09-Sep-24 9:20 PM View: | Rote William E. Senior Vice President, R&D | Travere Therapeutics, Inc. (TVTX) | 09-Sep-24 | Sale (Planned) | 4,387 | $11.52 | $50,538.20 | (5%) 88.84K to 84.45K | |
| 09-Sep-24 9:20 PM View: | Inrig Jula Chief Medical Officer | Travere Therapeutics, Inc. (TVTX) | 09-Sep-24 | Sale | 2,191 | $11.52 | $25,240.30 | (3%) 64.82K to 62.63K | |
| 09-Sep-24 9:20 PM View: | Reed Elizabeth E SVP, GC & Corporate Secretary | Travere Therapeutics, Inc. (TVTX) | 09-Sep-24 | Sale (Planned) | 4,387 | $11.52 | $50,538.20 | (5%) 83.02K to 78.63K | |
| 09-Sep-24 9:20 PM View: | Dube Eric M Chief Executive Officer Director | Travere Therapeutics, Inc. (TVTX) | 05-Sep-24 | Grant | 32,500 | -- | -- | 9% 350.6K to 383.1K | |
| 09-Sep-24 9:20 PM View: | Rote William E. Senior Vice President, R&D | Travere Therapeutics, Inc. (TVTX) | 05-Sep-24 | Grant | 6,750 | -- | -- | 8% 82.09K to 88.84K | |
| 09-Sep-24 9:20 PM View: | Inrig Jula Chief Medical Officer | Travere Therapeutics, Inc. (TVTX) | 05-Sep-24 | Grant | 6,750 | -- | -- | 12% 58.07K to 64.82K | |
| 09-Sep-24 9:20 PM View: | Cline Christopher R. Chief Financial Officer | Travere Therapeutics, Inc. (TVTX) | 05-Sep-24 | Grant | 6,750 | -- | -- | 10% 70.33K to 77.08K | |
| 09-Sep-24 9:20 PM View: | Reed Elizabeth E SVP, GC & Corporate Secretary | Travere Therapeutics, Inc. (TVTX) | 05-Sep-24 | Grant | 6,750 | -- | -- | 9% 76.27K to 83.02K | |
| 09-Sep-24 9:20 PM View: | Heerma Peter Chief Commercial Officer | Travere Therapeutics, Inc. (TVTX) | 05-Sep-24 | Grant | 6,750 | -- | -- | 7% 103.4K to 110.15K | |
| 05-Sep-24 9:30 PM View: | Cline Christopher R. Chief Financial Officer | Travere Therapeutics, Inc. (TVTX) | 04-Sep-24 | Sale | 514 | $9.51 | $4,887.78 | (< 1%) 70.85K to 70.33K | |
| 10-May-24 4:06 PM View: | Squarer Ron Director | Travere Therapeutics, Inc. (TVTX) | 08-May-24 | Grant | 6,500 | -- | -- | 29% 22.38K to 28.88K | |
| 10-May-24 4:05 PM View: | Poole Sandra Director | Travere Therapeutics, Inc. (TVTX) | 08-May-24 | Grant | 6,500 | -- | -- | 38% 17.0K to 23.5K | |
| 10-May-24 4:06 PM View: | Brinkley Ruth W Director | Travere Therapeutics, Inc. (TVTX) | 08-May-24 | Grant | 6,500 | -- | -- | 51% 12.75K to 19.25K | |
| 10-May-24 4:05 PM View: | Lyons Gary A Director | Travere Therapeutics, Inc. (TVTX) | 08-May-24 | Grant | 6,500 | -- | -- | 15% 44.5K to 51.0K | |
| 10-May-24 4:06 PM View: | Orwin John A Director | Travere Therapeutics, Inc. (TVTX) | 08-May-24 | Grant | 6,500 | -- | -- | 29% 22.38K to 28.88K | |
| 10-May-24 4:05 PM View: | Baynes Roy D. Director | Travere Therapeutics, Inc. (TVTX) | 08-May-24 | Grant | 6,500 | -- | -- | 27% 24.5K to 31.0K | |
| 10-May-24 4:05 PM View: | Coughlin Timothy P Director | Travere Therapeutics, Inc. (TVTX) | 08-May-24 | Grant | 6,500 | -- | -- | 15% 42.5K to 49.0K | |
| 10-May-24 4:05 PM View: | Meckler Jeffrey A Director | Travere Therapeutics, Inc. (TVTX) | 08-May-24 | Grant | 6,500 | -- | -- | 9% 74.5K to 81.0K | |
| 10-May-24 4:05 PM View: | Bruhn Suzanne Louise Director | Travere Therapeutics, Inc. (TVTX) | 08-May-24 | Grant | 6,500 | -- | -- | 41% 15.75K to 22.25K | |
| 12-Apr-24 4:05 PM View: | Cline Christopher R. Chief Financial Officer | Travere Therapeutics, Inc. (TVTX) | 11-Apr-24 | Sale | 54 | $6.74 | $363.96 | (< 1%) 70.9K to 70.85K | |
| 02-Feb-24 4:05 PM View: | Reed Elizabeth E SVP, GC & Corporate Secretary | Travere Therapeutics, Inc. (TVTX) | 01-Feb-24 | Sale (Planned) | 2,590 | $8.86 | $22,947.40 | (3%) 78.86K to 76.27K | |
| 02-Feb-24 4:06 PM View: | Dube Eric M Chief Executive Officer Director | Travere Therapeutics, Inc. (TVTX) | 01-Feb-24 | Sale | 9,106 | $8.53 | $77,693.30 | (2%) 369.72K to 360.62K | |
| 02-Feb-24 4:05 PM View: | Heerma Peter Chief Commercial Officer | Travere Therapeutics, Inc. (TVTX) | 01-Feb-24 | Sale | 4,195 | $8.53 | $35,788.80 | (4%) 103.7K to 99.5K | |
| 02-Feb-24 4:05 PM View: | Calvin Sandra SVP, Chief Accounting Officer | Travere Therapeutics, Inc. (TVTX) | 01-Feb-24 | Sale | 2,820 | $8.53 | $24,058.00 | (5%) 54.84K to 52.02K | |
| 02-Feb-24 4:05 PM View: | Rote William E. Senior Vice President, R&D | Travere Therapeutics, Inc. (TVTX) | 01-Feb-24 | Sale | 2,174 | $8.53 | $18,547.70 | (3%) 85.48K to 83.31K | |
| 02-Feb-24 4:06 PM View: | Dube Eric M Chief Executive Officer Director | Travere Therapeutics, Inc. (TVTX) | 01-Feb-24 | Sale (Planned) | 10,016 | $8.86 | $88,741.80 | (3%) 360.62K to 350.6K | |
| 02-Feb-24 4:05 PM View: | Rote William E. Senior Vice President, R&D | Travere Therapeutics, Inc. (TVTX) | 01-Feb-24 | Sale (Planned) | 2,590 | $8.86 | $22,947.40 | (3%) 83.31K to 80.72K | |
| 02-Feb-24 4:05 PM View: | Cline Christopher R. Chief Financial Officer | Travere Therapeutics, Inc. (TVTX) | 01-Feb-24 | Sale | 3,818 | $8.53 | $32,572.50 | (5%) 74.72K to 70.9K | |
| 02-Feb-24 4:05 PM View: | Reed Elizabeth E SVP, GC & Corporate Secretary | Travere Therapeutics, Inc. (TVTX) | 01-Feb-24 | Sale | 2,174 | $8.53 | $18,547.90 | (3%) 81.03K to 78.86K | |
| 02-Feb-24 4:05 PM View: | Inrig Jula Chief Medical Officer | Travere Therapeutics, Inc. (TVTX) | 01-Feb-24 | Sale | 2,174 | $8.53 | $18,546.60 | (4%) 60.25K to 58.07K | |
| 02-Feb-24 4:05 PM View: | Cline Christopher R. Chief Financial Officer | Travere Therapeutics, Inc. (TVTX) | 31-Jan-24 | Grant | 25,000 | -- | -- | 50% 49.72K to 74.72K | |
| 02-Feb-24 4:05 PM View: | Reed Elizabeth E SVP, GC & Corporate Secretary | Travere Therapeutics, Inc. (TVTX) | 31-Jan-24 | Grant | 25,000 | -- | -- | 45% 56.03K to 81.03K | |
| 02-Feb-24 4:06 PM View: | Dube Eric M Chief Executive Officer Director | Travere Therapeutics, Inc. (TVTX) | 31-Jan-24 | Grant | 135,000 | -- | -- | 58% 234.72K to 369.72K | |
| 02-Feb-24 4:05 PM View: | Heerma Peter Chief Commercial Officer | Travere Therapeutics, Inc. (TVTX) | 31-Jan-24 | Grant | 25,000 | -- | -- | 32% 78.7K to 103.7K | |
| 02-Feb-24 4:05 PM View: | Calvin Sandra SVP, Chief Accounting Officer | Travere Therapeutics, Inc. (TVTX) | 31-Jan-24 | Grant | 13,500 | -- | -- | 33% 41.34K to 54.84K | |
| 02-Feb-24 4:05 PM View: | Rote William E. Senior Vice President, R&D | Travere Therapeutics, Inc. (TVTX) | 31-Jan-24 | Grant | 25,000 | -- | -- | 41% 60.48K to 85.48K | |
| 02-Feb-24 4:05 PM View: | Inrig Jula Chief Medical Officer | Travere Therapeutics, Inc. (TVTX) | 31-Jan-24 | Grant | 25,000 | -- | -- | 71% 35.25K to 60.25K | |
| 25-Jan-24 4:10 PM View: | Heerma Peter Chief Commercial Officer | Travere Therapeutics, Inc. (TVTX) | 23-Jan-24 | Sale | 1,559 | $9.07 | $14,137.60 | (2%) 80.26K to 78.7K | |
| 25-Jan-24 4:10 PM View: | Calvin Sandra SVP, Chief Accounting Officer | Travere Therapeutics, Inc. (TVTX) | 23-Jan-24 | Sale | 910 | $9.07 | $8,252.24 | (2%) 42.25K to 41.34K | |
| 25-Jan-24 4:10 PM View: | Rote William E. Senior Vice President, R&D | Travere Therapeutics, Inc. (TVTX) | 23-Jan-24 | Sale (Planned) | 2,062 | $8.96 | $18,475.50 | (3%) 62.55K to 60.48K | |
| 25-Jan-24 4:10 PM View: | Cline Christopher R. Chief Financial Officer | Travere Therapeutics, Inc. (TVTX) | 23-Jan-24 | Sale | 853 | $9.07 | $7,735.35 | (2%) 50.57K to 49.72K | |
| 25-Jan-24 4:10 PM View: | Reed Elizabeth E SVP, GC & Corporate Secretary | Travere Therapeutics, Inc. (TVTX) | 23-Jan-24 | Sale (Planned) | 2,062 | $8.96 | $18,475.50 | (4%) 58.1K to 56.03K |
